62075-55-2

Basic information

• Product Name: 2,2-Dimethyl-1,3-Dioxolane-4-Carboxylic Acid
• Synonyms: 2,2-Dimethyl-1,3-Dioxolane-4-Carboxylic Acid;1,3-Dioxolane-4-carboxylic acid, 2,2-dimethyl-;2,2-Dimethyl-1,3-dioxolane-4-carboxylic
• CAS NO: 62075-55-2
• Molecular Formula: C6H10O4
• Molecular Weight: 146.1412
• Product Categories: Heterocycles series
• Mol File: 62075-55-2.mol
• Article Data: 41

Chemical Properties

• Boiling Point: 244.151 °C at 760 mmHg
• Flash Point: 101.605 °C
• Appearance: /
• Density: 1.203 g/cm³
• Vapor Pressure: 0.01mmHg at 25°C
• Refractive Index: 1.447
• CAS DataBase Reference: 2,2-Dimethyl-1,3-Dioxolane-4-Carboxylic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-Dimethyl-1,3-Dioxolane-4-Carboxylic Acid(62075-55-2)
• EPA Substance Registry System: 2,2-Dimethyl-1,3-Dioxolane-4-Carboxylic Acid(62075-55-2)

Safety Data

• Hazardous Substances Data: 62075-55-2(Hazardous Substances Data)

Usage

General Description

2,2-Dimethyl-1,3-dioxolane-4-carboxylic acid is a chemical compound with the molecular formula C7H12O4. It is a carboxylic acid with a dioxolane ring and two methyl substituents. 2,2-Dimethyl-1,3-dioxolane-4-carboxylic acid is often used in pharmaceutical research and drug development due to its potential biological activities. It has been studied for its antimicrobial and antifungal properties and has also been investigated for its potential use in the treatment of various diseases. Additionally, 2,2-Dimethyl-1,3-dioxolane-4-carboxylic acid has been utilized in organic synthesis as a building block for the preparation of more complex molecules.

InChI:InChI=1/C6H10O4/c1-6(2)9-3-4(10-6)5(7)8/h4H,3H2,1-2H3,(H,7,8)

Upstream product

• 100-79-8 (R,S)-2,2-dimethyl-1,3-dioxolane-4-methanol 
• 14028-61-6 potassium (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 15186-48-8 2,3-isopropylidene-glyceraldehyde 
• 1707-77-3 1,2:5,6-di-O-isopropylidene-D-mannitol 
• 60456-21-5 methyl (4S)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 52373-72-5 methyl (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 22323-82-6 (S)-(+)-(2,2-dimethyl-[1,3]dioxolan-4-yl)methanol 
• 55032-17-2 (4R)-4-benzyloxycarbonyl-2,2-dimethyl-1,3-dioxolane 
• 108865-84-5 methyl 2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 134036-81-0 (4S,5S)-5-[(R)-((R)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-hydroxy-methyl]-2,2-dimethyl-[1,3]dioxolane-4-carboxylic acid anion 
• 14131-84-1 2,3:5,6-di-O-isopropylidene-α-D-mannofuranose 
• 7306-64-1 2,3,5,6-di-O-isopropylidene-D-mannono-1,4-lactone 
• 5736-03-8 (d,l) isopropylidene glyceraldehyde 
• 117205-81-9 potassium (4S)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 

Downstream Products

• 148065-34-3 (R)-2,2-dimethyl-1,3-dioxolane-4-carboxamide 
• 99566-52-6 (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanone 
• 60456-21-5 methyl (4S)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 90493-96-2 2,2-dimethyl-1,3-dioxolane-4-carboxylic acid chloride 
• 52373-72-5 methyl (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 

Relevant articles and documents

ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

H-Phosphonate Synthesis and Biological Evaluation of an Immunomodulatory Phosphoglycolipid from Thermophilic Bacteria

The synthesis of a library of bacterial phosphoglycolipid, PGL-1, is described. Key features of the synthesis include regioselective esterification of the primary alcohol of the diacylglycerol moiety and an H-phosphonate method to install the phosphate in PGL-1 in comparison with earlier reported procedures. A representative set of PGL-1 analogues was prepared and evaluated for their biological activities. Results showed that the immunological activity of PGL-1 is dependent on the chain lengths of the fatty acids.

TARGETED COMPOSITIONS

The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).